XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration and Other Agreements - I-Mab Biopharma (Details) - USD ($)
$ in Thousands
 1 Months Ended 3 Months Ended
Jul. 31, 2019
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Jul. 09, 2019
Collaboration And Other Agreements [Line Items]          
Revenues   $ 16,881 $ 13,682    
Deferred revenue, current   3,520   $ 4,456  
Deferred revenue, net of current portion   7,260   6,926  
I-Mab | I-Mab Biopharma Collaboration and License Agreement          
Collaboration And Other Agreements [Line Items]          
Non-refundable upfront payment $ 15,000        
Potential development and regulatory milestone payments under agreement         $ 135,000
Estimated variable consideration $ 1,000        
Revenues   600 $ 1,100    
Deferred revenue   10,800   11,400  
Deferred revenue, current   3,500   4,500  
Deferred revenue, net of current portion   $ 7,300   $ 6,900  
I-Mab | I-Mab Biopharma Collaboration and License Agreement | Maximum          
Collaboration And Other Agreements [Line Items]          
Potential proceeds from royalties (percent) 20.00%